Moderna has been rebuked by ... not be seen as anything other than promotion of Spikevax,” the PMCPA said. The presentation ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax ... Pfizer's application was from an open-label study in Israel involving ...

Shares in Moderna have been under pressure after the ... The biotech has said it should make $6 billion from its Spikevax vaccine in 2023, after reporting third-quarter sales of $1.8 billion ...

COVID-19: The Company reported $1.8 billion in Spikevax ... label extension study. The Company intends to begin generating pivotal trial data in 2024. Methylmalonic acidemia (MMA) therapeutic ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

The Company reported $1.8 billion in Spikevax® sales in the third quarter of 2024, which includes $1.2 billion of U.S. sales and $0.6 billion of international sales. Moderna's updated mRNA COVID ...